-
Je něco špatně v tomto záznamu ?
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
S. Delimpasi, MV. Mateos, HW. Auner, M. Gavriatopoulou, MA. Dimopoulos, H. Quach, H. Pylypenko, R. Hájek, X. Leleu, TK. Dolai, DK. Sinha, CP. Venner, R. Benjamin, MK. Garg, V. Doronin, Y. Levy, P. Moreau, Y. Chai, M. Arazy, J. Shah, S. Shacham,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu dopisy, randomizované kontrolované studie, práce podpořená grantem
NLK
Free Medical Journals
od 1998 do Před 1 rokem
Wiley Free Content
od 1996 do Před 1 rokem
PubMed
34882831
DOI
10.1002/ajh.26434
Knihovny.cz E-zdroje
- MeSH
- bortezomib aplikace a dávkování MeSH
- dexamethason aplikace a dávkování MeSH
- hydraziny aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mnohočetný myelom * farmakoterapie mortalita MeSH
- nemoci ledvin * farmakoterapie mortalita MeSH
- přežití bez známek nemoci MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování MeSH
- triazoly aplikace a dávkování MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
Alexandra Hospital School of Medicine National and Kapodistrian University of Athens Athens Greece
Baylor University Medical Center Dallas Texas USA
City Clinical Hospital 40 Moscow Russian Federation
Cross Cancer Institute Edmonton Alberta Canada
Dana Farber Cancer Institute Boston Massachusetts USA
Department of Hematology Cherkassy Regional Oncological Center Cherkassy Ukraine
Department of Hematology CHU la Miletrie and Inserm CIC 1402 Poitiers France
General Hospital Evangelismos Athens Greece
Hospital Universitario de Salamanca Salamanca Spain
Karyopharm Therapeutics Newton Massachusetts USA
Kings College Hospital NHS Foundation Trust London UK
Medical University of Silesia Katowice Poland
Nil Ratan Sircar Medical College and Hospital Kolkata India
School of Medicine National and Kapodistrian University of Athens Athens Greece
St Vincent's Hospital University of Melbourne Fitzroy Victoria Australia
State Cancer Institute Indira Gandhi Institute of Medical Sciences Patna India
The Hugh and Josseline Langmuir Centre for Myeloma Research Imperial College London London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010806
- 003
- CZ-PrNML
- 005
- 20220506125755.0
- 007
- ta
- 008
- 220425s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.26434 $2 doi
- 035 __
- $a (PubMed)34882831
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Delimpasi, Sosana $u General Hospital Evangelismos, Athens, Greece $1 https://orcid.org/0000000175237510
- 245 10
- $a Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study / $c S. Delimpasi, MV. Mateos, HW. Auner, M. Gavriatopoulou, MA. Dimopoulos, H. Quach, H. Pylypenko, R. Hájek, X. Leleu, TK. Dolai, DK. Sinha, CP. Venner, R. Benjamin, MK. Garg, V. Doronin, Y. Levy, P. Moreau, Y. Chai, M. Arazy, J. Shah, S. Shacham, MG. Kauffman, PG. Richardson, S. Grosicki
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
- 650 _2
- $a bortezomib $x aplikace a dávkování $7 D000069286
- 650 _2
- $a dexamethason $x aplikace a dávkování $7 D003907
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydraziny $x aplikace a dávkování $7 D006834
- 650 12
- $a nemoci ledvin $x farmakoterapie $x mortalita $7 D007674
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a triazoly $x aplikace a dávkování $7 D014230
- 655 _2
- $a dopisy $7 D016422
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mateos, Maria Victoria $u Hospital Universitario de Salamanca, Salamanca, Spain
- 700 1_
- $a Auner, Holger W $u The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK $1 https://orcid.org/0000000340400642
- 700 1_
- $a Gavriatopoulou, Maria $u Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000262441229
- 700 1_
- $a Dimopoulos, Meletios A $u School of Medicine, National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000189903254
- 700 1_
- $a Quach, Hang $u St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia
- 700 1_
- $a Pylypenko, Halyna $u Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine
- 700 1_
- $a Hájek, Roman $u Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Leleu, Xavier $u Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France
- 700 1_
- $a Dolai, Tuphan Kanti $u Nil Ratan Sircar Medical College and Hospital, Kolkata, India
- 700 1_
- $a Sinha, Dinesh Kumar $u State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India
- 700 1_
- $a Venner, Christopher P $u Cross Cancer Institute, Edmonton, Alberta, Canada $1 https://orcid.org/0000000347014285
- 700 1_
- $a Benjamin, Reuben $u Kings College Hospital NHS Foundation Trust, London, UK
- 700 1_
- $a Garg, Mamta Krishnan $u University Hospitals of Leicester NHS Trust, Leicester, UK
- 700 1_
- $a Doronin, Vadim $u City Clinical Hospital #40, Moscow, Russian Federation
- 700 1_
- $a Levy, Yair $u Baylor University Medical Center, Dallas, Texas, USA
- 700 1_
- $a Moreau, Philippe $u University of Nantes, Nantes, France $1 https://orcid.org/0000000317808746
- 700 1_
- $a Chai, Yi $u Karyopharm Therapeutics, Newton, Massachusetts, USA
- 700 1_
- $a Arazy, Melina $u Karyopharm Therapeutics, Newton, Massachusetts, USA
- 700 1_
- $a Shah, Jatin $u Karyopharm Therapeutics, Newton, Massachusetts, USA
- 700 1_
- $a Shacham, Sharon $u Karyopharm Therapeutics, Newton, Massachusetts, USA
- 700 1_
- $a Kauffman, Michael G $u Karyopharm Therapeutics, Newton, Massachusetts, USA
- 700 1_
- $a Richardson, Paul G $u Dana-Farber Cancer Institute, Boston, Massachusetts, USA $1 https://orcid.org/0000000274268865
- 700 1_
- $a Grosicki, Sebastian $u Medical University of Silesia, Katowice, Poland
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 97, č. 3 (2022), s. E83-E86
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34882831 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125747 $b ABA008
- 999 __
- $a ok $b bmc $g 1788767 $s 1162004
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 97 $c 3 $d E83-E86 $e 20211229 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- LZP __
- $a Pubmed-20220425